TORONTO, Apr. 22, 2015 /PRNewswire/ -- Axxess Pharma Inc. (OTC: AXXE) a specialty pharmaceutical and nutritional supplements company is pleased to announce they have signed a long-term manufacturing, marketing and distribution agreement with 8E6Tong Private Company Ltd (Tong)., a Singapore-registered company with a manufacturing facility located in Tongxiang, China.
Under the agreement, Tong will be launching its own brand of products using Axxess' patented formula. Tongs products will be sold online, world-wide and in select retail outlets. Axxess Pharma projects minimum sales of $525,000 USD in the first year and $4,308,000 USD in the initial 5 year term of the license.
Tong is focused on the production, marketing, and distribution of health sciences products to improve the quality of life. The facility has been involved in the application of environmental science and green chemistry since 2010.
"This deal represents a major milestone for Axxess Pharma, and validates the value of our Intellectual Property. Revenues are expected to begin in the third quarter 2015 and accelerate year over year." stated Dr. Bagi President of Axxess Pharma Inc.
About Axxess Pharma Inc.:
Axxess Pharma Inc. is a Nevada Corporation operating through its wholly owned Canadian Subsidiary: Axxess Pharma Canada Inc., headquartered in Toronto. Axxess is a specialty Health Care Products Company dedicated to improving health and quality of life by offering select medicines, nutritional supplements and over the counter remedies all across the Americas. Axxess's goal is to bring additional products to the market and provide new, innovative options for better health spanning areas such as high cholesterol, blood pressure, acute pain -- to optimal health management through improved nutritional supplements. To learn more about our new products TapouT Extreme Muscle Growth and TapouT Muscle Recovery, please visit: http://buytapoutme.com and http://www.tapoutmusclerecovery.com.
For more information, please visit www.axxesspharmainc.com, or contact Investor Relations at (973) 351-3868.
About Authentic Brands Group, LLC
Authentic Brands Group, is a brand development, licensing, and entertainment company. In conjunction with Leonard Green & Partners, ABG's mandate to acquire, manage, and elevate long-term value in consumer, celebrity, and media brands. Headquartered in New York City, ABG's mission is to further enhance brand equity through partnering with best-in-class licensees and retail partnerships. ABG's global portfolio of world-renowned brands includes Marilyn Monroe®, Mini Marilyn™, Muhammad Ali®, Elvis Presley®, Juicy Couture®, Judith Leiber®, Adrienne Vittadini®, Taryn Rose®, Hickey Freeman®, Hart Schaffner Marx®, Palm Beach®, Misook®, Prince®, Spyder®, Airwalk®, Above The Rim®, Vision Street Wear®, Hind®, Ektelon®, Viking®, Bobby Jones®, TapouT®, Sportcraft®. www.abg-nyc.com.
Safe Harbor Statement
Statements about the Company's future expectations and all other statements in this press release other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby.
The above information contains information relating to the Company that is based on the beliefs of the Company and/or its management, as well as assumptions made by any information currently available to the Company or its management. When used in this document, the words "anticipate," "estimate," "expect," "intend," "plans," "projects," and similar expressions, as they relate to the Company or its management, are intended to identify forward-looking statements. Such statements reflect the current view of the Company regarding future events and are subject to certain risks, uncertainties and assumptions, including the risks and uncertainties noted. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove to be incorrect, actual results may vary materially from those described herein as anticipated, believed considered in light of the accompanying meaningful cautionary statements herein. Factors that could cause results to differ include, but are not limited to, successful performance of internal plans, the impact of competitive services and pricing and general economic risks, estimated, expected, intended or projected. In each instance, forward-looking information should be and uncertainties.
SOURCE Axxess Pharma, Inc